| 31.29 -0.07 (-0.22%) | 04-18 07:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.21 |
1-year : | 14.26 |
| Resists | First : | 10.46 |
Second : | 12.21 |
| Pivot price | 9.99  |
|||
| Supports | First : | 9.8 |
Second : | 9.39 |
| MAs | MA(5) : | 9.8 |
MA(20) : | 10.02 |
| MA(100) : | 9.55 |
MA(250) : | 8.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.4 |
D(3) : | 38.9 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 10.46 | Low : | 7.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNFCA ] has closed above bottom band by 47.1%. Bollinger Bands are 12.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10 - 10.04 | 10.04 - 10.07 |
| Low: | 9.74 - 9.78 | 9.78 - 9.83 |
| Close: | 9.9 - 9.96 | 9.96 - 10.02 |
Mon, 22 Mar 2021
SNCA Stock: Seneca Biopharma Shares Rocket Ahead of Merger, Reverse Stock Split Meeting - InvestorPlace
Wed, 01 Apr 2020
Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Thu, 19 Mar 2020
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's ... - Yahoo Finance
Mon, 28 Oct 2019
Neuralstem Becomes Seneca Biopharma - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 18 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 39.5 (%) |
| Held by Institutions | 39 (%) |
| Shares Short | 112 (K) |
| Shares Short P.Month | 144 (K) |
| EPS | 1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.68 |
| Profit Margin | 7.7 % |
| Operating Margin | 11.5 % |
| Return on Assets (ttm) | 2.2 % |
| Return on Equity (ttm) | 13.9 % |
| Qtrly Rev. Growth | -18.3 % |
| Gross Profit (p.s.) | 12.91 |
| Sales Per Share | 28.25 |
| EBITDA (p.s.) | 4.85 |
| Qtrly Earnings Growth | -64.6 % |
| Operating Cash Flow | 164 (M) |
| Levered Free Cash Flow | 226 (M) |
| PE Ratio | 5.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0.35 |
| Price to Cash Flow | 1.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|